These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1225 related articles for article (PubMed ID: 28657667)
21. Germline mutations in cancer susceptibility genes in high grade serous ovarian cancer in Serbia. Krivokuca A; Boljevic I; Jovandic S; Magic Z; Mandic A; Tomasevic Z; Brankovic-Magic M J Hum Genet; 2019 Apr; 64(4):281-290. PubMed ID: 30651582 [TBL] [Abstract][Full Text] [Related]
22. Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families. Catucci I; Milgrom R; Kushnir A; Laitman Y; Paluch-Shimon S; Volorio S; Ficarazzi F; Bernard L; Radice P; Friedman E; Peterlongo P Fam Cancer; 2012 Sep; 11(3):483-91. PubMed ID: 22692731 [TBL] [Abstract][Full Text] [Related]
23. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer. Francies FZ; Wainstein T; De Leeneer K; Cairns A; Murdoch M; Nietz S; Cubasch H; Poppe B; Van Maerken T; Crombez B; Coene I; Kerr R; Slabbert JP; Vral A; Krause A; Baeyens A; Claes KB BMC Cancer; 2015 Nov; 15():912. PubMed ID: 26577449 [TBL] [Abstract][Full Text] [Related]
24. Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. Fewings E; Larionov A; Redman J; Goldgraben MA; Scarth J; Richardson S; Brewer C; Davidson R; Ellis I; Evans DG; Halliday D; Izatt L; Marks P; McConnell V; Verbist L; Mayes R; Clark GR; Hadfield J; Chin SF; Teixeira MR; Giger OT; Hardwick R; di Pietro M; O'Donovan M; Pharoah P; Caldas C; Fitzgerald RC; Tischkowitz M Lancet Gastroenterol Hepatol; 2018 Jul; 3(7):489-498. PubMed ID: 29706558 [TBL] [Abstract][Full Text] [Related]
25. Growing recognition of the role for rare missense substitutions in breast cancer susceptibility. Tavtigian SV; Chenevix-Trench G Biomark Med; 2014; 8(4):589-603. PubMed ID: 24796624 [TBL] [Abstract][Full Text] [Related]
28. Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model. Lee AJ; Cunningham AP; Tischkowitz M; Simard J; Pharoah PD; Easton DF; Antoniou AC Genet Med; 2016 Dec; 18(12):1190-1198. PubMed ID: 27464310 [TBL] [Abstract][Full Text] [Related]
29. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity. Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368 [TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical findings and clinicopathological features of breast cancers with pathogenic germline mutations in Non-BRCA genes. Singh K; Scalia J; Legare R; Quddus MR; Sung CJ Hum Pathol; 2024 Apr; 146():49-56. PubMed ID: 38608781 [TBL] [Abstract][Full Text] [Related]
31. Association of germline rare pathogenic mutations in guideline-recommended genes with prostate cancer progression: A meta-analysis. Shi Z; Lu L; Resurreccion WK; Yang W; Wei J; Wang Q; Engelmann V; Zheng SL; Cooney KA; Isaacs WB; Helfand BT; Lu J; Xu J Prostate; 2022 Jan; 82(1):107-119. PubMed ID: 34674288 [TBL] [Abstract][Full Text] [Related]
32. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations. Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317 [TBL] [Abstract][Full Text] [Related]
33. Detection of Germline Mutations in Patients with Epithelial Ovarian Cancer Using Multi-gene Panels: Beyond BRCA1/2. Eoh KJ; Kim JE; Park HS; Lee ST; Park JS; Han JW; Lee JY; Kim S; Kim SW; Kim JH; Kim YT; Nam EJ Cancer Res Treat; 2018 Jul; 50(3):917-925. PubMed ID: 29020732 [TBL] [Abstract][Full Text] [Related]
34. The guidelines for clinical practice for carriers of germline mutations in hereditary breast, ovarian, prostate, and pancreatic cancer predisposition genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 (4.2024). Kleiblová P; Novotný J; Cibula D; Curtisová V; Dubová O; Foretová L; Germanová A; Janatová M; Havránek O; Hojsáková M; Hudcová M; Koudová M; Krutílková V; Palacova M; Paulich S; Petrakova K; Presl J; Puchmajerová A; Soukupová J; Šenkeříková M; Šimková Z; Štěpánková H; Šubrt I; Tachecí I; Tesner P; Urban O; Veselá K; Vilímová Š; Vlčková Z; Vočka M; Weinberger V; Zikán M; Zimovjanová M; Kleibl Z Klin Onkol; 2024; 38(4):292-299. PubMed ID: 39174333 [TBL] [Abstract][Full Text] [Related]
35. Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer. Park JS; Lee ST; Nam EJ; Han JW; Lee JY; Kim J; Kim TI; Park HS BMC Cancer; 2018 Jan; 18(1):83. PubMed ID: 29338689 [TBL] [Abstract][Full Text] [Related]
36. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. Ramus SJ; Song H; Dicks E; Tyrer JP; Rosenthal AN; Intermaggio MP; Fraser L; Gentry-Maharaj A; Hayward J; Philpott S; Anderson C; Edlund CK; Conti D; Harrington P; Barrowdale D; Bowtell DD; Alsop K; Mitchell G; ; Cicek MS; Cunningham JM; Fridley BL; Alsop J; Jimenez-Linan M; Poblete S; Lele S; Sucheston-Campbell L; Moysich KB; Sieh W; McGuire V; Lester J; Bogdanova N; Dürst M; Hillemanns P; ; Odunsi K; Whittemore AS; Karlan BY; Dörk T; Goode EL; Menon U; Jacobs IJ; Antoniou AC; Pharoah PD; Gayther SA J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26315354 [TBL] [Abstract][Full Text] [Related]
37. Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results. Pritzlaff M; Summerour P; McFarland R; Li S; Reineke P; Dolinsky JS; Goldgar DE; Shimelis H; Couch FJ; Chao EC; LaDuca H Breast Cancer Res Treat; 2017 Feb; 161(3):575-586. PubMed ID: 28008555 [TBL] [Abstract][Full Text] [Related]
38. Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories? Byrnes GB; Southey MC; Hopper JL Breast Cancer Res; 2008; 10(3):208. PubMed ID: 18557994 [TBL] [Abstract][Full Text] [Related]
39. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer. Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279 [TBL] [Abstract][Full Text] [Related]
40. Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer. Chen B; Zhang G; Li X; Ren C; Wang Y; Li K; Mok H; Cao L; Wen L; Jia M; Li C; Guo L; Wei G; Lin J; Li Y; Zhang Y; Han-Zhang H; Liu J; Lizaso A; Liao N Aging (Albany NY); 2020 Feb; 12(4):3140-3155. PubMed ID: 32091409 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]